Physical activity and COVID-19: an observational and Mendelian randomisation study

Xiaomeng Zhang¹, Xue Li¹,², Ziwén Sun³,⁴, Yazhou He¹,⁵, Wei Xu¹, Harry Campbell¹, Malcolm G Dunlop⁵, Maria Timofeeva⁶,⁷, Evropi Theodoratou¹,⁷

¹Centre for Global Health, Usher Institute, The University of Edinburgh, Edinburgh, UK
²School of Public Health and the Second Affiliated Hospital, Zhejiang University, Hangzhou, China
³School of Design and Arts, Beijing Institute of Technology, Beijing, China
⁴Edinburgh School of Architecture and Landscape Architecture, The University of Edinburgh, Edinburgh, UK
⁵Colon Cancer Genetics Group, Cancer Research UK Edinburgh Centre and Medical Research Council Human Genetics Unit, Medical Research Council Institute of Genetics and Molecular Medicine, The University of Edinburgh, Edinburgh, United Kingdom
⁶DIAS, Danish Institute for Advanced Study, Department of Public Health, University of Southern Denmark, Odense, Denmark
⁷Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, The University of Edinburgh, Edinburgh, UK

Correspondence to:
Evropi Theodoratou
Centre for Global Health
Usher Institute
University of Edinburgh
Edinburgh, UK
e.theodoratou@ed.ac.uk

Maria Timofeeva
Danish Institute for Advanced Study (D-IAS)
Department of Public Health
University of Southern Denmark
J.B. Winsløws Vej 9
DK-5000 Odense C
mtimofeeva@health.sdu.dk

Background: Physical activity (PA) is known to be a protective lifestyle factor against several non-communicable diseases while its impact on infectious diseases, including Coronavirus Disease 2019 (COVID-19) is not as clear.

Methods: We performed univariate and multivariate logistic regression to identify associations between both objectively and subjectively measured PA collected prospectively and COVID-19 related outcomes (overall COVID-19, inpatient COVID-19, outpatient COVID-19, and COVID-19 death) in the UK Biobank cohort. Subsequently, we tested causality by using Mendelian randomisation (MR) analyses.

Results: In the multivariable model, the increased acceleration vector magnitude PA (AMPA) is associated with a decreased probability of overall and outpatient COVID-19 with an odds ratio (OR) and 95% confidence interval (CI) of 0.80 (0.69, 0.93) and 0.74 (0.58, 0.95), respectively. No association is found between self-reported moderate-to-vigorous PA (MVPA) and COVID-19 related outcomes. No association is found by MR analyses.

Conclusions: Our results indicate a protective effect of objectively measured PA and COVID-19 outcomes (outpatient COVID-19 and overall COVID-19) independent of age, sex, measures of obesity, and smoking status. Although the MR analyses do not support a causal association, that may be due to limited power. We conclude that policies to encourage and facilitate exercise at a population level during the pandemic should be considered.
Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was declared a pandemic on March 11, 2020, by the World Health Organisation (WHO). By October 16th, 2020, a total of 39,023,292 patients had been diagnosed, with 1,099,586 confirmed deaths globally [1]. National responses to the pandemic including a range of non-pharmacological interventions (NPIs) have been adopted by countries at nation-wide, state-wide, or city-wide levels. The restrictions imposed by governments during the outbreak have had a substantial impact on patterns of physical activity (PA) within populations. For example, an online survey conducted in Canada indicated that 40.5% of physically inactive individuals became less active and 33% became more active; 22.4% of physically active individuals became less active and 40.3% became more active during lockdown time [2].

PA is known to be a protective lifestyle factor for a number of non-communicable diseases (eg, cancer and cardiovascular disease) and ageing processes (eg, immunosenescence) [3-5]. However, evidence of the role of PA on respiratory viral infections remains weak, especially for highly contagious viruses like SARS-CoV-2. Since doing exercise could compromise social distancing measures and increase opportunities for contracting the virus (probably indoors more than outdoors), it is unclear whether being physically active is a beneficial lifestyle factor for respiratory viral infections. Effects of PA on COVID-19 could be confounded by the effects of obesity. Viral pathogenesis has been reported to be greater in obese or overweight individuals and obesity has been suggested as a risk factor for COVID-19 [6,7]. In this study, we analysed whether PA influences the risk of COVID-19 in a prospective observational study by adjusting measures of obesity and smoking status. To avoid possible confounding effects induced by observational studies, we further investigated any associations between genetic predisposition of PA and COVID-19 by applying Mendelian Randomisation (MR) analyses.

MATERIALS AND METHODS

Data set

The UK Biobank (UKBB) is a prospective cohort study including more than 500,000 participants aged from 40 to 69 years in the United Kingdom. In this study, participants who have not been tested positive for SARS-CoV-2 and not died of COVID-19 were taken as controls. We removed from the controls the following participants in a sensitivity analysis: i) Those who tested negative since test results could have been false negative; ii) Participants, who were not from England, since all COVID-19 test results were provided by NHS England only; iii) Participants who died before 01/01/2020. We used both self-reported moderate-to-vigorous PA (MVPA) and acceleration vector magnitude PA (AMPA) as measures of PA. We took body mass index (BMI), waist circumference and hip circumference as measures of obesity in the prospective observational study. The detail of MVPA, AMPA and measures of obesity data were described in the supplementary method.

The UKBB released COVID-19 test results with the date of the specimen taken, specimen type (eg, nasal and throat), the testing laboratory, whether the patient was an inpatient or outpatient when the sample was taken and SARS-CoV-2 testing results. Inpatient samples included inpatient infections, samples taken in emergency departments and health care related infections. From 16/03/2020 to 29/06/2020, there were 14,439 SARS-CoV-2 test results among UKBB participants with 1,596 participants having at least one SARS-CoV-2 positive result and 7,898 participants having one or more negative results. Of these individuals, 7,187 were inpatients and 2,307 were outpatients. We analysed four COVID-19 related outcomes: overall COVID-19, included all patients (inpatients, outpatients or deaths); inpatient COVID-19, included all inpatients with at least one positive SARS-CoV-2 testing result; outpatient COVID-19, included outpatients who tested SARS-CoV-2 positive at least once; COVID-19 death, included death caused by clinical and epidemiological diagnosed COVID-19 (both primary and contributory causes of death).

Subsequently, we performed MR analyses to test the causality between PA and COVID-19 in the UKBB. The detailed description of genotyping, quality control and genetic imputation have been described previously [8]. From a total of 488,366 participants in the UKBB with genotype data, 149,110 samples were excluded due to consent withdrawals, non-white British ethnic background, sex mismatch, sex aneuploidy, high missing rate/outlier, and kinship inference. The genetic instruments for MVPA and AMPA were extracted from the largest available genome-wide association study (GWAS) data sets [9,10]. Seven and five common genetic variants were extracted for MVPA and AMPA respectively after considering linkage disequilibrium (LD) ($r^2$>0.2). Then, we performed multivariable MR to adjust BMI. The effect estimates of PA SNPs on BMI were extracted from a BMI GWAS [11].
Statistical analyses

To describe the characteristics of participants, mean and standard deviation (SD) were presented for continuous covariates, and number (N) and percentage (%) were presented for categorical covariates. We performed both univariate and multivariate logistic regression analyses to test the association between two measures of PA and four COVID-19 related outcomes. In the multivariate logistic regression model, we first added age and sex as covariates, then we further added measures of obesity or overweight (waist circumference, hip circumference, and BMI), and finally, we added smoking measures (smoking status, exposure to smoking at home and exposure to smoking out of home). The details of the covariates can be found in Bycroft et al [12]. Since measures of obesity or overweight tend to be correlated, we analysed the Pearson correlation coefficients among BMI, waist circumference and hip circumference. Table S1 in the Online Supplementary Document shows that BMI, waist circumference and hip circumference are significantly correlated, but the correlation coefficients are less than 0.1. Multicollinearity would not be an issue in our multivariable models.

For the MR analysis, we tested the association between genetic instruments of the exposures and COVID-19 by performing multivariate logistic regression adjusting for age, sex, the first 10 principal components (PCs), and the assessment centre in UKBB. The causal effects and the corresponding standard errors of exposures on the outcome were calculated by using a random effect inverse-variate weighted (IVW) method [13]. We evaluated the heterogeneity among the causal effects of each variant (Cochran’s Q statistic) and a P less than 0.10 was regarded as statistically significant heterogeneity. We performed MR-Egger [14] as a sensitivity analysis to explore the potential bias introduced by horizontal pleiotropy.

The P threshold is set at 0.05 for all the analyses. All statistical analyses were performed on R v3.6.1 (Foundation for Statistical Computing, Vienna, Austria).

RESULTS

The characteristics of participants in the four outcome groups (overall COVID-19, inpatient COVID-19, outpatient COVID-19, and COVID-19 death), and the included controls are described in Table 1. Patients who died from COVID-19 had the highest average age (74.7) while outpatients had the lowest average age (27.5).

Table 1. Characteristics of UK Biobank participants

|                 | Overall COVID-19 cases | Inpatient COVID-19 cases | Outpatient COVID-19 cases | COVID-19 deaths | Controls | Controls* |
|-----------------|------------------------|--------------------------|---------------------------|-----------------|----------|-----------|
|                 | mean (SD)/n(%)         | mean (SD)/n(%)           | mean (SD)/n(%)            | mean (SD)/n(%)  | mean (SD)/n(%) | mean (SD)/n(%) |
| All participants| 1746 (0.4%)            | 1020 (0.2%)              | 576 (0.1%)                | 390 (0.1%)      | 500738 (99.7%) | 415596 (99.7%) |
| Age             | 68.8 (9.2)             | 69.4 (8.9)               | 66.0 (9.4)                | 74.7 (6.0)      | 68.5 (8.1)  | 68.1 (8.1)  |
| Sex:            |                        |                          |                           |                 |          |           |
| Male            | 924 (52.9%)            | 570 (55.9%)              | 264 (45.8%)               | 255 (63.9%)     | 268549 (54.5%) | 185494 (44.6%) |
| Female          | 822 (47.1%)            | 450 (44.1%)              | 312 (54.2%)               | 144 (36.1%)     | 224885 (45.5%) | 230102 (55.4%) |
| MVPA (MET-minutes/week) | 990.4 (1310.8) | 1039.0 (1356.1) | 898.7 (1236.7) | 1017.0 (1057.9) | 973.8 (1269.0) | 974.6 (1268.1) |
| AMPA (milli-gravities) | 26.7 (8.6)/ 26.6 (8.9)/ | 27.4 (8.1)/               | 24.1 (8.1)/               | 28.0 (8.2)/     | 28.1 (8.2)/ | 28.1 (8.2)/ |
|                 | (n=215)                | (n=122)                  | (n=79)                    | (n=36)          | (n=96460)  | (n=83748)  |
| BMI (kg/m²)     | 27.5 (4.9)             | 27.5 (4.8)               | 27.7 (5.0)                | 27.6 (4.7)      | 27.4 (4.8)  | 27.4 (4.8)  |
| Waist circumference (cm) | 90.8 (14.0)        | 91.3 (14.5)              | 90.2 (13.2)               | 90.7 (14.6)     | 90.3 (13.5) | 90.3 (13.5) |
| Hip circumference (cm) | 103.1 (9.5)        | 102.9 (9.8)              | 103.4 (8.8)               | 103.2 (9.3)     | 103.4 (9.3) | 103.4 (9.2) |
| Smoking status: |                        |                          |                           |                 |          |           |
| Never           | 780 (48.9%)            | 462 (45.3%)              | 318 (55.2%)               | 148 (37.1%)     | 269014 (54.5%) | 231192 (35.6%) |
| Previous        | 619 (38.8%)            | 429 (42.0%)              | 190 (33.0%)               | 186 (46.6%)     | 169392 (34.3%) | 140876 (33.9%) |
| Current         | 179 (11.2%)            | 116 (11.4%)              | 63 (10.9%)                | 60 (15.0%)      | 51748 (10.5%) | 41182 (9.9%)  |
| Unknown         | 18 (1.1%)              | 13 (1.3%)                | 5 (0.9%)                  | 5 (1.3%)        | 3880 (0.8%)  | 1595 (0.6%)  |
| Exposure to smoking at home (hour/week) | 0.5 (4.1)       | 0.5 (4.5)                | 0.5 (3.8)                 | 0.4 (4.0)       | 0.5 (4.4)  | 0.5 (4.5)  |
| Exposure to smoking out of home (hour/week) | 0.4 (2.3)      | 0.4 (2.3)                | 0.4 (2.4)                 | 0.4 (3.4)       | 0.4 (2.4)  | 0.4 (2.5)  |

COVID-19 – coronavirus disease 2019, N – number, SD – standard deviation, BMI – body mass index, MVPA – self-reported moderate-to-vigorous physical activity, AMPA – acceleration vector magnitude physical activity

*A control group that excludes participants who have tested negative for SARS-CoV-2, who are not in England, and who died before 1 January 2020.
age (66.0). The proportion of males was the highest for the COVID-19 death group (63.9%) and the lowest for the outpatient COVID-19 group (45.8%). Participants in the inpatient COVID-19 group had the longest MVPA time while participants in the COVID-19 death group had the shortest. For AMPA, participants in the control group had the longest AMPA time while patients who died from COVID-19 had the shortest. The results of univariate and multivariate logistic regression of two measures of PA on the four outcomes are presented in Table 2. The results of MR analyses are presented in Figure 1 and Table 3.

A total of 500758 participants (96460 participants have AMPA data) from the UKBB were included as controls of the observational analyses. For the COVID-19 test result records, 1596 patients were COVID-19 positive, of these, 1020 were inpatients and 576 were outpatients. In addition, 399 participants had died of COVID-19 (with 376 deaths having COVID-19 as the primary cause of death), in which 249 had SARS-CoV-2 positive results. In the multivariate logistic regression models, AMPA is associated with de-

---

**Figure 1.** Scatter plots of results from Mendelian randomisation (MR) analysis. **Panel A.** Scatter plot of AMPA on COVID-19. **Panel B.** Scatter plot of MVPA on COVID-19. MVPA – moderate-to-vigorous physical activity, COVID-19 – coronavirus disease 2019, AMPA – acceleration vector magnitude physical activity.
Table 2. Association analyses between measures of physical activity and four COVID-19 related outcomes

| OR (95%CI) | P-value | OR (95%CI) | P-value | OR (95%CI) | P-value | OR (95%CI) | P-value | OR (95%CI) | P-value |
|------------|---------|------------|---------|------------|---------|------------|---------|------------|---------|
| Physical activity | 1.01 (0.97, 1.06) | 0.584 (0.73, 0.98) | 0.021 (0.99, 1.11) | 0.104 (0.68, 1.00) | 0.056 (0.86, 1.02) | 0.156 (0.74, 1.16) | 0.092 (0.94, 1.14) | 0.495 (0.94, 1.14) | 0.004 (0.38, 0.83) |
| Physical activity | 1.01 (0.97, 1.06) | 0.591 (0.69, 0.92) | 0.003 (0.99, 1.11) | 0.105 (0.69, 1.02) | 0.086 (0.86, 1.02) | 0.152 (0.58, 0.95) | 0.74 (0.94, 1.14) | 0.017 (0.53, 1.17) | 0.239 |
| Age | 1.00 (1.00, 1.01) | 0.153 (0.95, 0.99) | 0.97 (0.97, 1.02) | 3.09×10^-4 (0.97, 1.02) | 1.00 (0.95, 0.97) | 0.754 (0.88, 0.93) | 2.81×10^-13 (1.11, 1.15) | 0.90 (1.11, 1.15) | 1.13 (1.11, 1.15) | 3.47×10^-10 (1.10, 1.20) | 1.18 (1.10, 1.20) |
| Sex: Male | 1.34 (1.22, 1.47) | 1.09×10^-4 (1.04, 1.18) | 0.204 (1.33, 1.70) | 1.69×10^-10 (1.27, 2.62) | 0.001 (0.87, 1.01) | 0.784 (0.54, 1.33) | 0.468 (1.63, 2.45) | 0.8 (0.94, 1.14) | 0.78 (0.52, 1.17) | 0.235 |
| Waist circumference | 1.00 (1.10, 1.01) | 0.93 (0.95, 0.99) | 0.003 (0.99, 1.11) | 0.108 (0.97, 1.01) | 0.096 (0.87, 1.03) | 0.023 (0.58, 0.95) | 0.74 (0.94, 1.14) | 0.019 (0.94, 1.14) | 0.891 |
| Hip circumference | 1.00 (1.00, 1.01) | 1.00 (0.99, 1.02) | 0.871 (0.99, 1.00) | 0.101 (0.98, 1.02) | 0.093 (0.97, 1.02) | 0.884 (0.97, 1.02) | 0.652 (0.97, 1.02) | 0.099 (0.95, 1.03) | 0.644 |
| BMI | 1.00 (1.00, 1.01) | 0.315 (0.98, 1.04) | 0.52 (0.99, 1.02) | 0.67 (0.96, 1.04) | 0.981 (0.99, 1.03) | 0.264 (0.98, 1.07) | 1.01 (0.99, 1.03) | 0.505 (0.92, 1.06) | 0.761 |
| Physical activity | 1.01 (0.95, 1.06) | 0.876 (0.69, 0.96) | 0.012 (0.69, 0.96) | 0.166 (0.98, 1.11) | 0.85 (0.85, 1.03) | 0.129 (0.85, 1.03) | 0.155 (0.86, 1.03) | 0.79 (0.86, 1.03) | 0.078 (0.90, 1.11) | 0.061 (0.48, 1.14) | 0.172 |
| Age | 1.00 (1.00, 1.00) | 1.44 (0.96, 0.99) | 0.01 (1.01, 1.02) | 4.31×10^-4 (0.98, 1.01) | 6.58 (0.95, 0.97) | 4.26×10^-12 (0.87, 0.93) | 1.46×10^-10 (0.87, 0.93) | 1.13 (1.11, 1.15) | 4.64×10^-10 (1.09, 1.12) | 1.13 (1.10, 1.16) | 0.004 (1.09, 1.12) |
| Sex: Male | 1.36 (1.22, 1.50) | 5.93×10^-9 (1.05, 1.18) | 0.021 (1.31, 1.17) | 2.98×10^-9 (1.31, 2.88) | 9.22×10^-9 (0.91, 1.30) | 0.373 (0.51, 1.39) | 0.505 (1.52, 2.37) | 1.00 (0.99, 1.01) | 1.26×10^-6 (0.98, 1.03) | 0.17 (0.98, 1.03) |
| Waist circumference | 1.00 (1.00, 1.01) | 0.086 (1.01, 1.02) | 0.133 (1.00, 1.01) | 0.013 (1.00, 1.01) | 0.033 (0.99, 1.01) | 0.747 (0.98, 1.01) | 0.723 (0.99, 1.01) | 0.56 (0.99, 1.01) | 1.00 (0.99, 1.01) | 0.0001 (0.99, 1.01) |
| Hip circumference | 1.00 (0.99, 1.01) | 0.127 (0.98, 1.01) | 0.793 (0.99, 1.00) | 0.076 (0.99, 1.00) | 0.775 (0.99, 1.01) | 0.962 (0.96, 1.01) | 0.25 (0.99, 1.01) | 0.916 (1.07, 1.04) | 0.821 |
| BMI | 1.00 (0.99, 1.01) | 0.449 (0.98, 1.04) | 0.375 (0.99, 1.02) | 0.738 (0.98, 1.01) | 0.456 (0.98, 1.02) | 0.486 (0.97, 1.06) | 0.574 (0.98, 1.03) | 0.394 (0.94, 1.08) | 0.844 |

Smoking status: Never (Reference)
Table 2. Continued

| Overall COVID-19 | Inpatients COVID-19 | Outpatients COVID-19 | COVID-19 DEATH |
|------------------|---------------------|----------------------|----------------|
| MVPA             | AMPA                | MVPA                 | AMPA           |
| (SUBJECTIVELY MEASURED) | (OBJECTIVELY MEASURED) | (SUBJECTIVELY MEASURED) | (OBJECTIVELY MEASURED) |
| OR     | OR     | P-value | OR     | OR     | P-value | OR     | OR     | P-value | OR     | OR     | P-value |
| (95%CI) | (95%CI) |         | (95%CI) | (95%CI) |         | (95%CI) | (95%CI) |         | (95%CI) | (95%CI) |         |
| Previous | 1.25   | 7.36×10^{-3} | 1.38   | 1.01   | 0.041  | 1.54×10^{-3} | 1.57   | 1.00   | 0.300  | 1.01   | 0.895  | 0.96   |
|          | (1.12, 1.40) |         | (1.01, 1.98) | (1.04, 2.36) |         | (1.01, 1.59) | (1.07, 2.11) |         | (0.57, 1.71) | (0.57, 1.71) |         | (0.57, 1.71) | (0.57, 1.71) |
| Current  | 1.25   | 0.008  | 1.76   | 1.23   | 0.067  | 1.95   | 1.09   | 0.566  | 0.041  | 2.60   | 1.34×10^{-1} | 3.37   |
|          | (1.06, 1.48) |         | (0.99, 2.84) | (0.99, 2.84) |         | (0.93, 2.15) | (1.07, 2.11) |         | (0.70, 3.25) | (1.87, 3.61) |         | (1.06, 1.37) |
| Exposure to smoking at home | 1.00   | 0.513  | 0.95   | 0.99   | 0.364  | 0.94   | 1.00   | 0.647  | 0.096  | 1.00   | 0.879  | 0.65   |
|          | (0.98, 1.01) |         | (0.85, 1.05) | (0.97, 1.01) |         | (0.82, 1.09) | (0.97, 1.02) |         | (0.82, 1.11) | (0.97, 1.02) |         | (0.70, 1.45) |
| Exposure to smoking out of home | 1.00   | 0.908  | 0.91   | 1.00   | 0.962  | 0.89   | 1.00   | 0.799  | 0.80   | 0.169  | 0.671  | 1.00   |
|          | (0.98, 1.02) |         | (0.79, 1.05) | (0.97, 1.03) |         | (0.73, 1.09) | (0.97, 1.04) |         | (0.58, 1.10) | (0.87, 1.05) |         | (0.87, 1.15) |

MVPA – self-reported moderate-to-vigorous physical activity. AMPA – acceleration vector magnitude physical activity. OR – odds ratio. CI – confidence interval.

DISCUSSION

Our study found that higher AMPA value was inversely associated with overall COVID-19 (1746 cases) and outpatient COVID-19 (576 cases). After adjusting for age, sex, measures of obesity in the multivariate model, the association between AMPA and overall COVID-19 persisted. The association between AMPA and COVID-19 appeared to be robust after adjusting for smoking status. No association was detected by observational analyses between AMPA and COVID-19. No causal effect was found in the MR analyses.

PA can benefit respiratory viralgens through increasing the endurance of the respiratory muscles or improving the immune response to respiratory virus infection. PA can benefit respiratory infection symptoms induced by COVID-19 in the early stage of the pandemic in the UK, most testing capacity may have been taken as a surrogate for comparably serious disease associated with COVID-19. The effect of AMPA was abrogated after adjusting for smoking status. The direct effect of AMPA on respiratory virus infection symptoms may have been mediated by exposure to smoking at home or smoking out of home.

Confounding by smoking at home or smoking out of home may explain the reduced risk of COVID-19 death while the association disappeared after adjusting for the other covariates. On the contrary, the association disappeared after adjusting for smoking status. No association was detected by observational analyses between AMPA and COVID-19. No causal effect was found in the MR analyses.

A total of 34277 participants with genotype data were included in the MR analyses after sample quality control. The effect estimates of the instrumental variables on COVID-19 test results are presented in Table S3 in the Online Supplementary Document. AMPA detected to be associated with lower risk of inpatient COVID-19 (OR: 0.81, 95% CI: 0.74–0.88). Further adjusting for smoking status, no association was detected by observational analyses between AMPA and COVID-19. No causal effect was found in the MR analyses.

Further adjusting for smoking status, no association was detected by observational analyses between AMPA and COVID-19. No causal effect was found in the MR analyses.

A total of 34277 participants with genotype data were included in the MR analyses after sample quality control. The effect estimates of the instrumental variables on COVID-19 test results are presented in Table S3 in the Online Supplementary Document. AMPA detected to be associated with lower risk of inpatient COVID-19 (OR: 0.81, 95% CI: 0.74–0.88). Further adjusting for smoking status, no association was detected by observational analyses between AMPA and COVID-19. No causal effect was found in the MR analyses.

A total of 34277 participants with genotype data were included in the MR analyses after sample quality control. The effect estimates of the instrumental variables on COVID-19 test results are presented in Table S3 in the Online Supplementary Document. AMPA detected to be associated with lower risk of inpatient COVID-19 (OR: 0.81, 95% CI: 0.74–0.88). Further adjusting for smoking status, no association was detected by observational analyses between AMPA and COVID-19. No causal effect was found in the MR analyses.

A total of 34277 participants with genotype data were included in the MR analyses after sample quality control. The effect estimates of the instrumental variables on COVID-19 test results are presented in Table S3 in the Online Supplementary Document. AMPA detected to be associated with lower risk of inpatient COVID-19 (OR: 0.81, 95% CI: 0.74–0.88). Further adjusting for smoking status, no association was detected by observational analyses between AMPA and COVID-19. No causal effect was found in the MR analyses.

A total of 34277 participants with genotype data were included in the MR analyses after sample quality control. The effect estimates of the instrumental variables on COVID-19 test results are presented in Table S3 in the Online Supplementary Document. AMPA detected to be associated with lower risk of inpatient COVID-19 (OR: 0.81, 95% CI: 0.74–0.88). Further adjusting for smoking status, no association was detected by observational analyses between AMPA and COVID-19. No causal effect was found in the MR analyses.
adjustment for other covariates, which highlighted the importance of the effect of age, gender, and other co-morbidities for COVID-19 death.

Published evidence shows that PA was not only associated with better physical health through pathways such as regulating immunity [19] but also could benefit mental health [20]. There is a possibility that the higher PA might be a proxy for better biological or mental health. Meanwhile, PA is associated with better socio-economic status and other healthy behaviours (eg, diet) [21] which may indicate a better adhesion to social distancing rules or using of personal protective equipment during a pandemic.

This is the first study to analyse the association between PA and COVID-19 quantitatively. One of the advantages of this study is that both objectively and subjectively measured PA were analysed. AMPA is widely considered as a relatively accurate measure of PA, whereas the main advantage of using MVPA is its cost-efficiency. MVPA and AMPA measures were compared in a large Norwegian study and the results indicated that people tend to report less moderate-intensity and more vigorous-intensity PA compared to AMPA regardless of gender and age [22]. Older adults also tended to exaggerate the reports of MVPA [22], perhaps because fragile individuals experienced stronger proprioception during exercise. In addition, self-reported questionnaires tended to record more intentional outdoor exercise while accelerometers measure all types of exercise [18,23]. During the pandemic, these differences may intensify. Another advantage of this study is that four COVID-19 outcomes were analysed. Although more data reflecting serious diseases related to COVID-19 is available, the four outcomes can still represent different severity of COVID-19 disease.

Our study has several limitations. First, participants of the UKBB tend to be healthier, leaner, and smoke less compared to the general population of the UK, especially for those who accepted the invitation to take part in the accelerometer aspect of the study. Furthermore, UKBB participants were recruited when aged 40 to 69 years old, and so may now have an even higher risk of severe COVID-19 disease. The lower obese/overweight and smoking rate and older age may result in an underestimation of the effects of obesity and smoking status. Second, the data for AMPA were obtained between 2013 and 2015, and older age related to a lower AMPA, which could lead to an underestimation of the true effect of AMPA on COVID-19 [22]. The data for MVPA and measures of obesity were acquired even earlier (2006-2010), so, the historical measures may not be a good proxy for current values. Combining the discrepancy between objectively and subjectively measured PA and the time gap may explain the different results of MVPA and AMPA on COVID-19 related outcomes. Third, the definition of COVID-19 severity group is not perfect, the potential contamination among each group may bias our results. Finally, testing practices and capacity changed over time in the UK, so the earlier data (data before 30/05/2020) represent a limited subset of COVID-19 infections. Due to the limited number of test results, the MR analyses had low power to detect a significant association.

### CONCLUSION

This study supports a protective effect of objectively measured PA on COVID-19 outcomes after adjusting for age, sex, measures of obesity, and smoking status. Associations tend to be observed in patients with relatively mild symptoms (outpatient COVID-19 and overall COVID-19 instead of inpatient COVID-19 and COVID-19 death). These results suggest that physically active people may have a lower chance to be diagnosed with COVID-19 in general. Although the MR analyses did not support a causal association, that may be due to limited power. In this study, we conclude that policies to encourage and facilitate exercise at a population level during the pandemic should be considered.

### Table 3. Results of Mendelian randomisation studies between physical activity exposures and overall COVID-19

|                          | OR (95%CI) | MVPA     | AMPA     |
|--------------------------|-----------|-----------|-----------|
|                          | P         | Phet      | Pr        | OR (95%CI) | P         | Phet      | Pr        |
| One-sample Mendelian randomisation: |           |           |           |           |           |           |           |
| IVW                      | 0.37 (0.03, 5.08) | 0.46      | /         | 0.28      | 1.36 (0.20, 9.21) | 0.76      | /         | 0.13      |
| MR-Egger                 | 0.01 (8.58×10^{-5}, 1061.38) | 0.43      | 0.53      | /         | 8.42×10^{-7} (4.56×10^{-11}, 0.16) | 0.02      | 0.02      | /         |
| Multivariable Mendelian randomisation adjusted BMI: |           |           |           |           |           |           |           |
| IVW                      | 0.39 (0.02, 6.92) | 0.52      | /         | 0.19      | 0.73 (0.12, 4.25) | 0.73      | /         | 0.3       |
| MR-Egger                 | 0.002 (1.60×10^{-8}, 1735.41) | 0.37      | 0.43      | /         | 7.66×10^{-6} (2.04×10^{-11}, 2.88) | 0.07      | 0.08      | /         |

COVID-19 – coronavirus disease 2019, MVPA – self-reported moderate-to-vigorous physical activity, AMPA – acceleration vector magnitude physical activity, BMI – body mass index, OR – odds ratio, CI – confidence interval, IVW – inverse variance weighted method, P het – P value for the intercept of MR-Egger’s test, P int – P values of χ² Q test for heterogeneity.
Acknowledgements: We would like to express our gratitude to the support from Edinburgh CRUK Cancer Research Centre as well as support from all trustees of the Darwin Trust of Edinburgh. This research has been conducted using the UK Biobank Resource under Application Number 10775. The research activities of UKBB were approved by the North West Multi-centre Research Ethics Committee (11/NW/0382) in relation to the process of participant invitation, assessment and follow-up procedures.

Availability of data and material: UK Biobank data are available through a procedure described at http://www.ukbiobank.ac.uk/using-the-resource/

Funding: This work was supported by Cancer Research UK programme grant to MD [grant number C348/A18927]; Cancer Research UK Career Development Fellowship to ET [grant number C31250/A22804]; The Darwin Trust of Edinburgh studentship to XZ.

Authors’ contributions: MGD, MT, and ET conceived this study. XZ, XL, MT and ET designed the methodology. XZ conducted data analysis and drafted the manuscript. XZ conducted data interpretation with ET, MT, and MGD. XL, ZS, YH, WX, HC, MGD, MT, and ET contributed to the manuscript drafting and revision.

Competing interests: Harry Campbell is the Co-Editor in Chief of the Journal of Global Health. To ensure that any possible conflict of interest relevant to the journal has been addressed, this article was reviewed according to best practice guidelines of international editorial organisations. The authors completed the ICMJE Unified Competing Interest form (available upon request from the corresponding author) and declare no conflicts of interest.

Additional material
Online Supplementary Document

1 WHO. Coronavirus disease (COVID-2019) situation reports 2020. Available: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200729-covid-19-sitrep-191.pdf?sfvrsn=2c327e9e_2. Accessed: 29 July 2020.
2 Lesser IA, Nienhuis CP. The Impact of COVID-19 on Physical Activity Behavior and Well-Being of Canadians. Int J Envir Res Public Health. 2020;17:3899. Medline:32486380 doi:10.3390/ijerph17113899
3 Rezende LFM, Sa TH, Markozannes G, Rey-Lopez JP, Lee IM, Tsilidis KK, et al. Physical activity and cancer: an umbrella review of the literature including 22 major anatomical sites and 770 000 cancer cases. Br J Sports Med. 2018;52:826-33. Medline:29146752 doi:10.1136/bjsports-2017-098391
4 Vasankari V, Husu P, Vaha-Yppa H, Suni J, Tokola K, Halonen J, et al. Association of objectively measured sedentary behaviour and physical activity with cardiovascular disease risk. Eur J Prev Cardiol. 2017;24:1311-8. Medline:28530126 doi:10.1177/2047487317711048
5 Sellami M, Gasm M, Denham J, Hayes LD, Stratton D, Padulo J, et al. Effects of Acute and Chronic Exercise on Immunological Parameters in the Elderly Aged: Can Physical Activity Counteract the Effects of Aging? Front Immunol. 2019;9:2187. Medline:30364079 doi:10.3389/fimmu.2018.02187
6 Leong A, Cole J, Brenner LN, Meigs JB, Florez JC, Mercader JM. Cardiometabolic Risk Factors for COVID-19 Susceptibility and Severity: A Mendelian Randomization Analysis. Medrxiv 2020. Available: https://www.medrxiv.org/content/10.1101/2020.08.26.20182709v1. Accessed: 1 November 2020.
7 Popkin BM, Du S, Green WD, Beck MA, Algith T, Herbst CH, et al. Individuals with obesity and COVID-19: A global perspective on the epidemiology and biological relationships. Obes Rev. 2020;21:e13128. Medline:32845580 doi:10.1111/obr.13128
8 Meng X, Li X, Timofeeva MN, He Y, Spiliopoulou A, Wei WQ, et al. Phenome-wide Mendelian-randomization study of genetically determined vitamin D on multiple health outcomes using the UK Biobank study. Int J Epidemiol. 2019;48:1425-34. Medline:31518429 doi:10.1093/ije/dyz182
9 Klimentidis YC, Raichlen DA, Bea J, Garcia DO, Wineinger NE, Mandarino LJ, et al. Genome-wide association study of habitual physical activity in over 377,000 UK Biobank participants identifies multiple variants including CADM2 and APOE. Int J Obes (Lond). 2018;42:1161-76. Medline:29899525 doi:10.1038/s41166-018-0120-3
10 Doherty A, Smith-Byrne K, Ferreira T, Holmes MV, Holmes C, Pulit SL, et al. GWAS identifies 14 loci for device-measured APOE. Int J Obes (Lond). 2018;42:1161-76. Medline:29899525 doi:10.1038/s41166-018-0120-3
11 Doherty A, Smith-Byrne K, Ferreira T, Holmes MV, Holmes C, Pulit SL, et al. GWAS identifies 14 loci for device-measured APOE. Int J Obes (Lond). 2018;42:1161-76. Medline:29899525 doi:10.1038/s41166-018-0120-3
12 Doherty A, Smith-Byrne K, Ferreira T, Holmes MV, Holmes C, Pulit SL, et al. GWAS identifies 14 loci for device-measured APOE. Int J Obes (Lond). 2018;42:1161-76. Medline:29899525 doi:10.1038/s41166-018-0120-3
13 Doherty A, Smith-Byrne K, Ferreira T, Holmes MV, Holmes C, Pulit SL, et al. GWAS identifies 14 loci for device-measured APOE. Int J Obes (Lond). 2018;42:1161-76. Medline:29899525 doi:10.1038/s41166-018-0120-3
14 Doherty A, Smith-Byrne K, Ferreira T, Holmes MV, Holmes C, Pulit SL, et al. GWAS identifies 14 loci for device-measured APOE. Int J Obes (Lond). 2018;42:1161-76. Medline:29899525 doi:10.1038/s41166-018-0120-3
15 Doherty A, Smith-Byrne K, Ferreira T, Holmes MV, Holmes C, Pulit SL, et al. GWAS identifies 14 loci for device-measured APOE. Int J Obes (Lond). 2018;42:1161-76. Medline:29899525 doi:10.1038/s41166-018-0120-3
Physical activity and COVID-19

Martin SA, Pence BD, Woods JA. Exercise and respiratory tract viral infections. Exerc Sport Sci Rev. 2009;37:157-64. Medline:19955864 doi: 10.1097/JES.0b013e3181b7b57b

Biobank U. Records of COVID-19 test results. 2020. Available: http://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=40100. Accessed: 25 June 2020.

Doherty A, Jackson D, Hammerla N, Plotz T, Olivier P, Granat MH, et al. Large Scale Population Assessment of Physical Activity Using Wrist Worn Accelerometers: The UK Biobank Study. PLoS One. 2017;12:e0169649. Medline:28146576 doi:10.1371/journal.pone.0169649

Simpson RJ, Kunz H, Agha N, Graff R. Exercise and the Regulation of Immune Functions. Prog Mol Biol Transl Sci. 2015;135:355-80. Medline:26477922 doi:10.1016/bs.pmbts.2015.08.001

White RL, Babic MJ, Parker PD, Lubans DR, Astell-Burt T, Lonsdale C. Domain-Specific Physical Activity and Mental Health: A Meta-analysis. Am J Prev Med. 2017;52:653-66. Medline:28153647 doi:10.1016/j.amepre.2016.12.008

Oude Groeniger J, Kamphuis CBM, Mackenbach JP, Beenackers MA, van Lenthe FJ. Are socio-economic inequalities in diet and physical activity a matter of social distinction? A cross-sectional study. Int J Public Health. 2019;64:1037-47. Medline:31187165 doi:10.1007/s00038-019-01268-3

Dyrstad SM, Hansen BH, Holme IM, Anderssen SA. Comparison of self-reported versus accelerometer-measured physical activity. Med Sci Sports Exerc. 2014;46:99-106. Medline:23793232 doi:10.1249/MSS.0b013e3182a0595f

Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003,35:1381-95. Medline:12900694 doi:10.1249/01.MSS.0000078924.61453.FB